Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACSS2 | Q9NR19 | 3/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.34 |
| ▸ | CDC7 | O00311 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19261619 | 0.85 | GRM2 (0.47) | ACSS2GRM2SMN1; SMN2 | |
| SCHEMBL24463113 | 0.81 | LMNA (0.40) | ACSS2KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL26790443 | 0.81 | ACSS2 (0.36) | ACSS2GRM2KMT2A | |
| SCHEMBL24463036 | 0.78 | MAPT (0.50) | KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL10238327 | 0.78 | MEN1 (0.47) | ACSS2GRM2KMT2AMEN1 | |
| SCHEMBL25270181 | 0.76 | MAP3K14 (0.42) | MAP3K14CDC7CDK2 | |
| SCHEMBL5419669 | 0.76 | KDM4E (0.44) | ACSS2KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL30425064 | 0.76 | MAP3K14 (0.42) | MAP3K14CDC7CDK2 | |
| SCHEMBL17378554 | 0.76 | KDM4E (0.45) | ACSS2AGPAT2KMT2ASMN1; SMN2 | |
| SCHEMBL26790445 | 0.76 | MAPT (0.49) | ACSS2KMT2AMAPK1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374015-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | KINNATE BIOPHARMA INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230374015-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | KINNATE BIOPHARMA INC. | 2023-11-23 | — | — | US | disclosed |
| CN-116096707-A | Inhibitors of fibroblast growth factor receptor kinase | 金耐特生物制药公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-116057045-A | Fibroblast growth factor receptor kinase inhibitors | 金耐特生物制药公司 | 2023-05-02 | — | — | CN | disclosed |
| EP-4161657-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | Kinnate Biopharma Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| EP-4161656-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | Kinnate Biopharma Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| US-11345681-B1 | Inhibitors of fibroblast growth factor receptor kinases | KINNATE BIOPHARMA INC. (US) | 2022-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374015-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | FGFR1, FGFR2, FGFR3 | ACSS2 965/4885GRM2 1599/4885MAP3K14 154/4885 |
| US-11345681-B1 | Inhibitors of fibroblast growth factor receptor kinases | FGFR1, FGFR2, FGFR3 | ACSS2 965/4885GRM2 1599/4885MAP3K14 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.